Presence of CYP2C9*3 Allele Increases Risk for Hypoglycemia in Type 2 Diabetic Patients Treated with Sulfonylureas

Citations Over TimeTop 10% of 2009 papers

Abstract

The presence of CYP2C9*3 appears to be protective for development of T2DM. Furthermore, in T2DM patients, CYP2C9*3 increases the risk of hypoglycemia when they are treated with sulfonylureas, possibly due to impaired metabolism of these drugs. CYP2C9 genotyping might thus be a useful tool for predicting adverse effects caused by sulfonylureas and help clinicians in safer prescribing of oral hypoglycemic agents. The potential T2DM protective effect of CYP2C9*3 allele requires further investigation.

Related Papers

• Synthesis and Herbicidal Activity of New Sulfonylurea Derivatives(2005)
• [Sulfonylurea-induced hypoglycemia. An iatrogenic and potentially fatal condition].(1997)
• Advance on the Development of Sulfonylurea Herbicide(2005)
• On the Security of Sulfonylurea in the Treatment of Type 2 Diabetes(2012)
• Research Progress of Sulfonylurea Herbicides(2005)